Morgan Stanley Vista Gen Therapeutics, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.12 - $0.3 $7,947 - $19,869	-66,233 Reduced 26.56%	183,153 $21,000
Q4 2022 Feb 14, 2023	BUY	$0.09 - $4.8 $8,505 - $453,633	94,507 Added 61.02%	249,386 $24,000
Q3 2022 Nov 14, 2022	BUY	$0.14 - $4.8 $3,495 - $119,836	24,966 Added 19.22%	154,879 $24,000
Q2 2022 Oct 27, 2022	SELL	$0.88 - $1.73 $523,919 - $1.03 Million	-595,363 Reduced 82.09%	129,913 $114,000
Q2 2022 Aug 15, 2022	SELL	$0.88 - $1.73 $523,919 - $1.03 Million	-595,363 Reduced 82.09%	129,913 $114,000
Q1 2022 Oct 27, 2022	BUY	$1.14 - $2.09 $678,713 - $1.24 Million	595,363 Added 458.28%	725,276 $899,000
Q1 2022 May 13, 2022	BUY	$1.14 - $2.09 $435,351 - $798,143	381,887 Added 111.21%	725,276 $899,000
Q4 2021 Feb 14, 2022	BUY	$1.67 - $2.76 $486,736 - $804,426	291,459 Added 561.25%	343,389 $669,000
Q3 2021 Nov 15, 2021	BUY	$2.62 - $3.45 $136,056 - $179,158	51,930 New	51,930 $142,000

27.1K

Ticker VTGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 206,836,000
Market Cap $610M
Description
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.